Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Merck Obtains Japanese Approval For Januvia Use With Insulin

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based Merck, Sharp & Dohme announced the approval of Januvia (sitagliptin) in combination use with insulin for type 2 diabetes

Tokyo-based Merck, Sharp & Dohme announced the approval of Januvia (sitagliptin) in combination use with insulin for type 2 diabetes.

Januvia was the first DPP-4 inhibitor to be approved in Japan. Launched in December 2009, the drug has been widely prescribed. Currently, the once-daily 50mg tablet is co-promoted with Ono Pharmaceutical as Glactiv (sitagliptin). Other DPP-4 inhibitors available in Japan include Equa (vildagliptin) from Novartis Pharma, Nippon Boehringer Ingelheim's Tradjenta (linagliptin) and Takeda Nesina (alogliptin). (Click here for more - Japanese language)

"MSD Januvia Obtains Additional Indication For Januvia With Insulin" - Mainichi News (9/21/2011)

Table

View full table

Tags:
Latest Headlines

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

Biogen Sees Improving Momentum In Slow Leqembi Launch

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Day One Springs Into Commercial Action With Ojemda Approval

See All
UsernamePublicRestriction

Register

SC079107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By